How to save money on prescriptions and give back

2023-10-06T12:35:00

(BPT) – Prescriptions can be expensive, but one company is committed to making communities healthier by making medicines more affordable. Since 2010, BuzzRx® customers have saved over $1 billion on prescription medications through their free prescription savings card, coupons, and mobile app.

While BuzzRx’s primary goal is to help people get the medications they need to stay healthy, its work doesn’t stop there. It’s the only prescription savings company that gives back year-round to their nonprofit partners like Make-A-Wish®.

For the last 10 years, through its corporate sponsorship with Make-A-Wish, BuzzRx has helped grant over 650 life-changing wishes. BuzzRx is always eager to go the extra mile for wish kids, whether through volunteering at an event, participating in a wish-granting, or providing wish enhancements. Their reach is national, but their impact remains local because BuzzRx’s donations go back to the nearest Make-A-Wish chapter where the card was used. The BuzzRx team, including their community-based Representatives, are proud to know their efforts are giving back to their local communities.

“The BuzzRx team is thrilled to be celebrating 10 years of granting wishes through our partnership with Make-A-Wish,” said Matthew Herfield, BuzzRx Chairman and CEO. “From day one, our company has wholeheartedly embraced its mission to spread hope, strength, and joy to children fighting life-threatening illnesses, and our passion for this cause has only grown stronger over time.”

Making a difference, one kid at a time

The BuzzRx team is extremely passionate about giving back to Make-A-Wish and believes wholeheartedly in the power of a wish. Here are just a few wishes the company has made possible.

Christian, a 9-year-old from Chicago, was diagnosed with a congenital heart condition when he was just a baby. Since then, he endured several surgeries and today is feeling good thanks to his supportive relatives, close monitoring of his condition, and daily medication. For Christian’s wish, he wanted to be a superhero, just like his favorite comic book character. In 2017, with sponsorship from BuzzRx, Make-A-Wish made his dream a reality! Christian helped save Chicago from “the bad guys” through a series of heroic actions across the city, and even had his own police escort!

In 2016, 5-year-old Wyatt was diagnosed with leukemia and underwent countless medical appointments, hospital stays, and chemotherapy sessions. “It’s been a tough time, but he’s such a strong little boy,” said Brittany, Wyatt’s Mom. In 2017, Make-A-Wish and BuzzRx granted Wyatt’s wish in West Melbourne, Florida. Wyatt’s heartwarming wish was to be an ice cream man so he could share his love for ice cream with his friends and family.

Audrey, a 12-year-old living in Arizona, has a passion for fashion! Her nervous system disorder and daily seizures caused by a stroke at birth didn’t stop her from pursuing her interest in fashion. When she learned she was eligible for a wish, Audrey knew exactly what she wanted. “I wish to wear a fancy, poufy dress and have my photos taken with my hair and makeup done just like the models in fashion magazines.” In 2021, BuzzRx sponsored Audrey’s wish, and she was able to realize her dream of having a fashion photoshoot.

In 2020, 2-year-old Lydia was diagnosed with retinoblastoma and endured countless rounds of chemotherapy and eye surgeries. 4-year-old Lydia’s greatest wish was to meet giraffes “at their house.” BuzzRx and Make-A-Wish made it possible for her to visit Animal Adventure Park in upstate New York, where she enjoyed personalized behind-the-scenes tours and experiences, including feeding giraffes!

These are just a few of the many wishes BuzzRx has made possible over the last decade through its partnership with Make-A-Wish. In celebration of 10 years of granting wishes, during the 10th month of the year, BuzzRx will donate $1 for every app download, up to $10,000.

“The promise of a wish can be transformative for a child with a critical illness,” said Leslie Motter, president and CEO of Make-A-Wish America. “When a wish comes true, it gives kids like Audrey the strength to fight and even overcome their illness. We’re grateful to celebrate ten years of partnership with BuzzRx to help more children reclaim their childhood and believe in brighter days ahead.”

The free BuzzRx card and coupons can help you save up to 80% on prescription medications at over 60,000 pharmacies nationwide and make more wishes come true. This October, download the free BuzzRx app to help grant more wishes for wish kids—the company will donate $1 to Make-A-Wish at no cost to you. To learn more, visit BuzzRx.com/wish.

Parenting hack: Fun ways to feed kids well

2023-10-05T17:41:00

(BPT) – Registered Dietitian Mia Syn, MS, RDN

Are your little ones turning up their noses at broccoli and scoffing at spinach? It’s time to bring out the secret ingredients — fun and laughter, plus maybe some hidden veggies. Here are my best tips for getting kids to gobble up healthy food that will have them begging for more!

1. Cook together: Cooking as a family can be fun and educational. Yes, it can also make a bit of a mess. But lean into it, I promise it’s worth it! When kids participate in meal preparation, they are more likely to try new foods and flavors. Plus getting them involved practices skills like measuring, chopping, stirring and following recipes — great for children’s overall development and gives them a great sense of accomplishment. Try a Taco Tuesday night with Kevin’s Cilantro Lime Chicken. The chicken is heat and serve, so it’s perfect for tiny hand participation. Pop it in your favorite tortillas and create a toppings bar for kids to make their own creations. Letting kids choose their own toppings provides an opportunity to cultivate autonomy and have a little fun!

2. Encourage family meals: Family meals are where it’s at! Eating together is a chance to bond and connect, not to mention savor some seriously delicious food. Make fuss-free and fun dinners a staple in your household by putting technology aside and focusing on the goodness at hand. Try upping the fun factor by playing some fun sing-a-long dinnertime music. Or pick up some colorful paper napkins with their favorite characters and let the kids choose Superman or SpongeBob. Studies show that kiddos who eat dinner with their families tend to have healthier diets overall. Take that, mac ‘n cheese on repeat!

3. Be a role model: Monkey see, monkey do! Your little ones learn by example, so be sure to model healthy eating habits yourself. Want your kids to eat their veggies? Then it’s time to show them how it’s done! You can even make it extra easy and delicious by trying out Kevin’s Natural Foods 5-minute meals. With a wide variety of flavors, like Thai Coconut Chicken and Korean BBQ Beef, these meals are not only healthy but also incredibly tasty. Add in some pre-washed veggies and dinner is served! By enjoying these convenient and nutritious options, you’ll show your kids that eating well can be both quick and satisfying.

Now get out there and help your kids build a healthy relationship with food and develop a taste for nutritious options! From being a role model to trying out Kevin’s Natural Foods 5-minute meals, taking small steps can make a big difference in your child’s health. So, start today, and don’t forget to add in the fun!

How Cancer Screening Led to a Diagnosis Before Symptoms

2023-10-04T06:01:01

(BPT) – At 54 years old, Valerie felt healthy and prided herself on being active. In her hometown of Flagstaff, Ariz., she could often be found exploring the outdoors, playing with her granddaughter or spending time with friends. She took a proactive approach to her health, so when she read a book that discussed breakthroughs in precision medicine, she was curious, especially when it came to new approaches to cancer screening.

Currently, there are only five recommended cancer screenings in the United States, including mammograms and colonoscopies. While early detection has been proven to significantly improve cancer survival rates and reduce the cost and complexity of cancer treatment, most cancers don’t have recommended screenings and are detected too late. Cancers without widespread screening recommendations represent 71% of all cancer diagnoses and 70% of cancer deaths in the U.S. among individuals aged 50-79.

Knowing she had some family history of cancer, Valerie wanted to know more. She researched a multi-cancer early detection test called Galleri®, which screens for a signal shared by multiple types of cancers through a single blood draw. When a cancer signal is detected, the test can predict the tissue type or organ associated with the cancer signal with high accuracy and help guide diagnostic evaluation.

Advocating for Her Health

Although she felt healthy and didn’t have any symptoms, Valerie was determined to advocate for her own health. She spoke with a few healthcare providers and worked with a physician who ordered the Galleri test.

“I received a call that there was a signal detected. My doctor quickly ordered an MRI but said he didn’t see cancer. However, the radiologist told me he had never seen a gallbladder with so many stones and that it needed to come out,” recalled Valerie.

Valerie had a successful surgery to remove her gallbladder, but there was more to her story. The day after the surgery, the pathology report came back and showed there was a 4.5-centimeter tumor in her gallbladder.

“Finding out I did have cancer allowed me to take action. We moved forward with my care plan, and I started on chemotherapy for six months,” Valerie said. “I feel like this test was made for me. I appreciate it so much. I’m going to be able to live my life because we found my gallbladder cancer so soon.”

Knowledge Empowers

Valerie is grateful she pushed to take the Galleri test, because it helped her find her cancer early and make informed decisions that were right for her. She was empowered to advocate for her own health and is now encouraging others to take an active role in their health journeys.

Valerie knows firsthand that knowledge empowers, but there’s an element of bravery required to request the test and hear the results.

“It takes courage for people to take the Galleri test, especially the first time, because there’s many kinds of cancers you could have,” she said. “Is it better not to know, or is it better to know? For me, it was better to know. That’s how I can sit here with energy and continue my life right now.”

“I just want to get the word out to as many people as possible, because this is something that has made such a difference for myself and my family,” she continued.

Learn More

The Galleri test must be prescribed by a healthcare provider and should be used in addition to recommended cancer screenings such as mammography, colonoscopy, prostate-specific antigen (PSA) test and/or cervical cancer screening. It is intended for use in adults with an elevated risk for cancer, such as those aged 50 or older.

The Galleri test does not detect a signal for all cancers, and not all cancers can be detected in the blood. False positive and false negative results do occur.

Based on a clinical study of people ages 50 to 79, around 1% are expected to receive a Cancer Signal Detected result, which includes predicted Cancer Signal Origin(s). After diagnostic evaluation, around 40% of people are expected to have a confirmed cancer diagnosis. The overall sensitivity in Galleri study participants with gallbladder cancer was 70.6% (0% for Stage I, 33.3% for Stage II, 75.0% for Stage III and 100% for Stage IV).

Learn more at galleri.com.

Important Safety Information

The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.

Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of “Cancer Signal Not Detected” does not rule out cancer. A test result of “Cancer Signal Detected” requires confirmatory diagnostic evaluation by medically established procedures (e.g., imaging) to confirm cancer.

If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur. Rx only.

Laboratory/Test Information

GRAIL’s clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the College of American Pathologists. The Galleri test was developed, and its performance characteristics were determined by GRAIL. The Galleri test has not been cleared or approved by the U.S. Food and Drug Administration. GRAIL’s clinical laboratory is regulated under CLIA to perform high-complexity testing. The Galleri test is intended for clinical purposes.

This retailer is thanking shoppers with extraordinary bonus offers this week

2023-10-02T11:53:00

(BPT) – An exclusive savings event is happening at Walgreens to celebrate and thank myWalgreens members with extraordinary bonus offers and Walgreens Cash rewards. myW™days will kick off on Oct. 4 and run through Oct. 7. With four days of daily deals and more, this is a great time to earn cash rewards ahead of the holiday shopping season. Plus, just in time for respiratory virus season, shoppers can also get a $20 Walgreens Cash reward bonus when they get their vaccines at Walgreens.

myWalgreens® members can take advantage of exclusive offers on Walgreens-branded items, for 30-minute Pickup or 1-Hour Delivery orders and online and in-store orders. To take advantage of these deals, be sure to sign up or log into your myWalgreens® account (it’s free to join!) to start unlocking deals now to clip and use throughout the course of the event:

1. Wednesday, Oct. 4: Earn 15% Walgreens Cash on Walgreens Branded Products

When you shop any Walgreens-branded product on Oct. 4, you’ll earn 15% Walgreens Cash rewards on your purchase. Then, apply those rewards toward future Walgreens purchases for even more savings.

2. Thursday, Oct. 5: Earn $10 Walgreens Cash on Pickup and Delivery Orders

Walgreens offers one-hour delivery (when you order before 7 p.m.) nationwide on more than 27,000 retail items, delivered right to your door. If you need it faster, select 30-Minute Pickup and your order will be packed and ready for you to grab at your local store. On Oct. 5, you’ll earn $10 Walgreens Cash when you spend $30+ on a 1-Hour Delivery or 30-Minute Pickup order.

3. Friday, Oct. 6: Extra Online Discounts

On Oct. 6, myWalgreens® members will earn an extra 25% off their $20 purchase using code WAG25 or an extra 30% off a $60 purchase using code WAG30 on eligible purchases sitewide.

4. Saturday, Oct. 7: Deeper Cash Rewards

If you’re shopping on Oct. 7, you’ll earn $20 Walgreens Cash rewards when you spend $45 or more on eligible purchases made in-store, online or on the Walgreens app. It pays to shop in the app as it allows you to clip app-exclusive deals and coupons from anywhere. Plus, the app shows your Walgreens Cash rewards balance in real time.

5. All Event Long: $20 Walgreens Cash rewards on Immunizations

As the respiratory virus season approaches, it’s important to take steps to protect yourself and those around you. To reward those who are doing so, Walgreens is offering $20 Cash rewards when you receive an immunization for flu, COVID-19, RSV or pneumonia during the myW days event. Limit three per member.

6. All Event Long: 15% Walgreens Cash on Eligible Purchases

Just for being a member during this event, Walgreens is offering 15% Walgreens Cash rewards on eligible purchases. Walgreens Cash rewards earned during myW days will be available for members to redeem on future Walgreens purchases for up to one year from when earned.

7. All Event Long: $25 Walgreens Cash with myWalgreens® Credit Card

When you open a myWalgreens® credit card during this event, you’ll receive an automatic $25 Walgreens Cash reward if you make a purchase with the card within 45 days.

myWalgreens® members can redeem the myW days promotions from anywhere, whether you choose to shop in-store or online.

To take advantage of the deals, members can begin clipping offers in their myWalgreens® account now online at walgreens.com/mywdays or in the Walgreens app.

Living with Tardive Dyskinesia and Mental Illness: A Testimonial

2023-10-02T07:01:00

(BPT) – Davitria lives with two mental illnesses and tardive dyskinesia.

This article was sponsored and developed by Neurocrine Biosciences, Inc. Davitria was compensated by Neurocrine Biosciences to share her story.

Every year during the first week of October, Mental Illness Awareness Week is recognized nationwide to raise awareness and support those living with a mental illness. More than one in five adults live with a mental illness in the United States, and of those, up to 30 percent of people who are taking antipsychotic treatment also develop a condition called tardive dyskinesia (TD). TD is a movement disorder associated with prolonged use of certain antipsychotics.

Davitria, an only child from Tennessee, has had a lifelong journey with mental illness and also lives with TD. Davitria’s journey with mental illness started when she was five years old and triggered after witnessing her parents have intense arguments. She believes discovering her passion for basketball as a child helped her cope.

“The coach of the boys’ basketball team walked past, pointed at me, and said ‘You play basketball?’ I said, ‘No, sir.’ He said, ‘You do now.’ I believe that man and basketball saved my life,” said Davitria.

Despite finding solace in playing basketball, later in her life, Davitria was diagnosed with major depressive disorder in college and bipolar disorder in 2015.

Over the years, Davitria was prescribed a variety of antidepressant and antipsychotic medications. Working with her healthcare providers, she found a treatment plan that helped control her underlying mental illnesses. But a few years later, she began to experience uncontrollable movements, first impacting her shoulder, then other body parts including her head, arms and mouth.

“For about three years, I suffered with these movements and saw different doctors. I started with my primary care physician, then switched to psychiatrists and then two neurologists,” said Davitria. She was finally referred to a nurse practitioner (NP), who diagnosed her with TD.

TD is a chronic condition that affects approximately 600,000 people in the U.S. It may lead to mild, moderate or severe uncontrollable, abnormal and repetitive movements in different parts of the body. These movements can impact people physically, socially and emotionally. People with TD have reported feeling judged, ashamed, and misunderstood.

As a dedicated basketball player and coach, Davitria valued her ability to be in control of her body. The uncontrollable movements quickly began to affect her, so her NP prescribed INGREZZA® (valbenazine) capsules. Only INGREZZA offers simple dosing that’s always one capsule, once daily to treat adults with the uncontrollable movements of TD.

INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with:

  • movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).

It is not known if INGREZZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

INGREZZA can cause serious side effects in people with Huntington’s disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA if you have Huntington’s disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.

Do not take INGREZZA if you are allergic to valbenazine, or any of the ingredients in INGREZZA.

Please see full Important Safety Information, including Boxed Warning, below and Prescribing Information.

After starting INGREZZA, Davitria saw a reduction in her movements and was able to return to the activities she enjoyed, including basketball and other everyday activities. “Now that I have fewer uncontrollable body movements, I feel like I can get back to doing my favorite things,” she said.

During this year’s Mental Illness Awareness Week, Davitria wants to share her story to raise awareness of TD, its impact, and the importance of working with healthcare professionals to find a once-daily treatment like INGREZZA that helps with the persistent, uncontrollable movements associated with TD.

“Mental Illness Awareness Week means more people will hear about mental health,” she said. “It is important to me to have the opportunity to help spread awareness about TD and empower people to seek the treatment they need, like how I did with INGREZZA.”

Visit INGREZZA.com to learn more about TD and talk to your doctor about possible treatment options, including INGREZZA.

Important Information

Approved Uses

INGREZZA® (valbenazine) capsules is a prescription medicine used to treat adults with:

  • movements in the face, tongue, or other body parts that cannot be controlled (tardive dyskinesia).
  • involuntary movements (chorea) of Huntington’s disease. INGREZZA does not cure the cause of involuntary movements, and it does not treat other symptoms of Huntington’s disease, such as problems with thinking or emotions.

It is not known if INGREZZA is safe and effective in children.

IMPORTANT SAFETY INFORMATION

INGREZZA can cause serious side effects in people with Huntington’s disease, including: depression, suicidal thoughts, or suicidal actions. Tell your healthcare provider before you start taking INGREZZA if you have Huntington’s disease and are depressed (have untreated depression or depression that is not well controlled by medicine) or have suicidal thoughts. Pay close attention to any changes, especially sudden changes, in mood, behaviors, thoughts, or feelings. This is especially important when INGREZZA is started and when the dose is changed. Call your healthcare provider right away if you become depressed, have unusual changes in mood or behavior, or have thoughts of hurting yourself.

Do not take INGREZZA if you:

  • are allergic to valbenazine, or any of the ingredients in INGREZZA.

INGREZZA may cause serious side effects, including:

  • Sudden swelling from an allergic reaction (angioedema). Sudden swelling has happened after the first dose or after many doses of INGREZZA. Signs and symptoms of angioedema include: swelling of your face, lips, throat, and other areas of your skin, difficulty swallowing or breathing, and raised, red areas on your skin (hives). Swelling in the throat can be life-threatening and can lead to death. Go to the nearest emergency room right away if you develop these signs and symptoms. Your healthcare provider should stop your treatment with INGREZZA.
  • Heart rhythm problems (QT prolongation). INGREZZA may cause a heart problem known as QT prolongation. Symptoms of QT prolongation may include: fast, slow, or irregular heartbeat, dizziness or fainting, or shortness of breath.

Tell your healthcare provider right away if you have a change in your heartbeat (a fast or irregular heartbeat), or if you faint.

  • Neuroleptic Malignant Syndrome (NMS): NMS is a serious condition that can lead to death. Call a healthcare provider right away or go to the nearest emergency room if you develop these symptoms and they do not have another obvious cause: high fever, stiff muscles, problems thinking, very fast or uneven heartbeat, or increased sweating.
  • Abnormal movements (Parkinson-like). Symptoms include: shaking, body stiffness, trouble moving or walking, or keeping your balance.

Before taking INGREZZA, tell your healthcare provider about all of your medical conditions including if you: have liver or heart problems, are pregnant or plan to become pregnant, or are breastfeeding or plan to breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

Sleepiness (sedation) is a common side effect with INGREZZA. While taking INGREZZA, do not drive a car or operate dangerous machinery until you know how INGREZZA affects you. Drinking alcohol and taking other drugs that may also cause sleepiness while you are taking INGREZZA may increase any sleepiness caused by INGREZZA.

The most common side effect of INGREZZA in people with tardive dyskinesia is sleepiness (somnolence).

The most common side effects of INGREZZA in people with Huntington’s disease are sleepiness (somnolence), allergic itching, rash, and trouble getting to sleep or staying asleep.

These are not all of the possible side effects of INGREZZA. Call your doctor for medical advice about side effects. You are encouraged to report negative side effects of prescription drugs to the FDA. Visit MedWatch at www.fda.gov/medwatch or call 1-800-FDA-1088.

Please see INGREZZA full Prescribing Information, including Boxed Warning.

This article was sponsored and developed by Neurocrine Biosciences Inc. Davitria was compensated by Neurocrine Biosciences to share her story.

©2023 Neurocrine Biosciences, Inc. All Rights Reserved. CP-VBZ-US-2936 10/2023

1 in 3 People Don’t Know They Have Afib, A Serious Heart Issue That Can Cause Problems If Undetected

2023-09-28T08:05:00

(BPT) – Atrial fibrillation (Afib) is a common cardiac arrhythmia, or heart rhythm disorder,[1] with an irregular and often very rapid heart rhythm. Afib is incredibly common, especially in older persons, and adults over the age of 40 have a one in four lifetime risk[2] of developing the condition. Today, around 6 million people in the U.S. have Afib, and the Centers for Disease Control and Prevention (CDC) projects that by 2030, this number will double to 12 million.[3] Even more concerning is that there are up to 1.5 million adults living with Afib who don’t know they have it.[4]

Potential Risks of Afib

Some people are aware of Afib the second they have an episode – they have symptoms of a heaving heart or palpitations. But others may have no awareness that they have Afib, with approximately one in three Afib patients experiencing no symptoms at the time of diagnosis.[5] But even if you can’t feel it, Afib can cause silent and ongoing damage to your heart,[6] making awareness and early detection vital.

Untreated Afib can lead to high-stakes health consequences, including a fivefold increase in risk of stroke[7] (and more severe strokes) and a threefold increase in heart failure.[8] Afib is responsible for one out of every seven strokes,[9] hospitalizes half a million people every year[10] and leads to 160,000 deaths per year.[11] Delayed diagnosis and treatment of Afib directly leads to these complications, but they can be prevented with prompt, clinically-proven, and widely available treatments.[12]

Getting Diagnosed Is Critical…

While Afib is treatable and treatment goals will vary based on your specific condition, you first need a diagnosis.

“Afib can be treated, and its complications can be prevented – which is why early detection and treatment are crucial. It’s important to raise awareness of Afib so we can help people get diagnosed and treated before they face the serious health consequences of Afib,” said Mellanie True Hills, founder of StopAfib.org and creator of National Atrial Fibrillation Awareness Month.

…But Hasn’t Always Been Easy

The path to Afib diagnosis hasn’t always been easy. It wasn’t long ago that you needed to be in the hospital to see a doctor and get an in-clinic electrocardiogram (ECG) to find out if you have Afib. Because Afib symptoms often come and go, and because the ECG needs to capture the exact time you are in Afib, getting a diagnosis has sometimes meant getting repeat ECGs or that the condition was missed altogether.

Today, doctors still widely use Holter monitors. These are wired, clunky devices that were introduced in the 1960s and are worn for 24 to 48 hours. Clinical studies have shown that the longer the recording period the better[13] – because again, Afib often comes and goes with some people going days or weeks without an episode. In fact, three out of four patients using a Holter monitor do not get a diagnosis on the first test.[14]

Hope for the Future

Now, even a smartwatch can tell you that you might have Afib by tracking your pulse to see if it becomes irregular, but the accuracy is not perfect. If you have any symptoms or get a smartwatch alert, you will likely need an ECG.

Now, modern ECG monitors, some of which are smaller than a dollar bill, can be worn at home and continuously record your heart’s electrical signal for longer than 24 to 48 hours if your doctor prescribes it. iRhythm has been creating these types of ECG monitors since 2008 and is now launching its next generation Zio® monitoring device, the Zio monitor. The device is small and discreet when worn, with no wires and no need to change batteries during the wear period.

Recordings from these Zio ECG monitoring devices continuously record your heart for up to 14 days – capturing up to 1.5 million heart beats[15] – and help doctors accurately diagnose Afib.

“If you or your loved one has symptoms of Afib or other arrhythmias, it’s worth talking to your physician or care team,” said Mintu Turakhia, MD, MAS, a cardiologist and the chief medical and scientific officer at iRhythm. “Getting diagnosed early is critical, and modern technology now allows patients to go about their daily lives uninterrupted. Our technology can meet patients where they are, ensuring they have the data to get a diagnosis for Afib or other heart rhythm conditions — or provide reassurance that their heart is beating normally.”

Early detection and treatment of arrhythmias are important to reduce the burden of cardiac disease.[16] Newer heart monitoring technology is helping in the shift to more preventative and proactive treatment and care, providing an effective way to diagnose Afib and protect your health.


[1] Atrial Fibrillation. Centers for Disease Control and Prevention (CDC), 2022. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm [accessed September 2023]
[2] Staerk, et al., Lifetime risk of atrial fibrillation according to optimal, borderline, or elevated levels of risk factors: cohort study based on longitudinal data from the Framingham Heart Study. BMJ. 2018
[3] Colilla S., et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. The American Journal of Cardiology, 2013.
[4] Turakhia MP, et al., Contemporary prevalence estimates of undiagnosed and diagnosed atrial fibrillation in the United States. Clin Cardiol, 2023.
[5] Sgreccia, et al., Comparing Outcomes in Asymptomatic and Symptomatic Atrial Fibrillation: A Systematic Review and Meta-Analysis of 81,462 Patients. Journal of Clinical Medicine MDPI, 2021.
[6] What is an arrhythmia? National Heart Lung and Blood Institute, 2022. https://www.nhlbi.nih.gov/health/arrhythmias Accessed November 18, 2022
[7] Wolf, et al., Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke, 1991.
[8] Kotecha, et al., Atrial fibrillation in heart failure: what should we do? Eur Heart J., 2015.
[9] Atrial Fibrillation. Centers for Disease Control and Prevention (CDC), 2022. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm [accessed September 2023]
[10] Nisar, et al., Trends in atrial fibrillation hospitalizations in the United States: A report using data from the National Hospital Discharge Survey. Indian Pacing and Electrophysiology Journal, 2018.
[11] Atrial Fibrillation. Centers for Disease Control and Prevention (CDC), 2022. https://www.cdc.gov/heartdisease/atrial_fibrillation.htm [accessed September 2023]
[12] Rilig et al. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation, 2022.
[13] Reynolds et al. Comparative effectiveness of ambulatory monitors for arrhythmia diagnosis: A retrospective analysis of Medicare beneficiaries managed with ambulatory cardiac monitors between 2017 and 2019. Accepted for ACC.23 presentation, presented at New Orleans, LA.
[14] Tsang, et al., Benefits of monitoring patients with mobile cardiac telemetry (MCT) compared with the Event or Holter monitors. Medical Devices: Evidence and Research, 2013.
[15] Data on file. iRhythm Technologies, 2019.
[16] Rilig et al. Early Rhythm Control in Patients With Atrial Fibrillation and High Comorbidity Burden. Circulation, 2022.

One man’s story gives hope to those with treatment-resistant depression

2023-09-28T10:49:00

(BPT) – When the COVID-19 pandemic hit in 2020, Ben, who had already been diagnosed with clinical depression in 2018, felt his depressive symptoms increase the more isolated he became. As an information technology consultant in New York City, his daily routine changed drastically. He woke up, immediately began work from bed and joined work meetings with his camera off with little to no participation.

Ben was in survival mode. Eventually, small tasks like showering, eating, sleeping, and attending meetings with his team felt overwhelming and close to impossible. After feeling like every day was a living nightmare, Ben decided to go to a new psychiatrist, who recommended he start taking antidepressants.

Finding the right treatment option isn’t an easy task. Like many people with clinical depression, Ben struggled to find a treatment that worked for him. He cycled through a couple of medications but, to his dismay, none of his depressive symptoms were relieved. Impatient and frustrated, he couldn’t believe it took a 12-week trial period for each new medication to see if it would work for him.

Eventually, after trying a few medications, Ben was diagnosed with treatment-resistant depression or TRD — a term that validated his experience cycling through a couple of treatments without relief. According to the Agency for Healthcare Research and Quality, TRD occurs when a patient has not achieved significant benefit with at least two different antidepressants of adequate dose and duration. Like Ben, about one-third of adults with depression may have this condition, according to a study published in the American Journal of Psychiatry.

Even with treatment and therapy, Ben continued to have depressive episodes. “One day, I received a last-minute meeting invite from my boss — I immediately went into a downward spiral,” he said. “Curled in a ball and sobbing, my chest pain was so severe that I thought I was having a heart attack. I could see the hospital through my window but had no motivation to walk across the street and ask for help.”

Soon after this episode, Ben moved across the country to live with his older sister in Oregon. Together, they researched many other treatment options. Ben was searching for a medication studied specifically to help someone like him and for the confidence that comes with a medicine approved by the U.S. Food and Drug Administration (FDA) specifically for his condition. During his search, he learned about a different treatment option for people diagnosed with TRD, called SPRAVATO® (esketamine) CIII nasal spray.

When he brought up this treatment option, Ben’s psychiatrist walked him through the risks and benefits and administration and dosing requirements, which include going into a certified SPRAVATO® treatment center twice a week for the first four weeks of treatment. They also discussed some of the most serious side effects of this treatment, including dizziness, sedation, dissociation, increases in blood pressure, the risk of abuse and misuse, and increased risk of suicidal thoughts or actions. As with all SPRAVATO® patients, Ben was enrolled in the Risk Evaluation and Mitigation Strategy (REMS) program to track any serious side effects he may experience.

Please see the Important Safety Information, including BOXED WARNINGS, and a list of side effects below.

Once Ben was enrolled in the REMS program, he was able to start his twice-weekly SPRAVATO® treatments in conjunction with an oral antidepressant.

“I started to feel clearer and lighter as my depressive symptoms improved after my treatments, which gave me a new perspective,” he said. “Through treatment and lots of work, my days are no longer completely consumed with self-hate and darkness but rather more self-love and light.”

And, although this treatment may not work for everyone, SPRAVATO® became a key piece of Ben’s treatment plan to help him manage his TRD during one of the most difficult times in his life. Ben advises others who may be struggling to have open communication: “I understand how alone and isolated you may feel when you’re navigating depression, but just know you are not alone. Ask for help — your support system can help advocate for you when you’re unable to advocate for yourself.”

If you or someone you know needs mental health support, call or text 988 Suicide and Crisis Lifeline, available nationwide to people with a mental health counselor.

IMPORTANT SAFETY INFORMATION

What is SPRAVATO® (esketamine) CIII nasal spray?

SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:

  • Adults with treatment-resistant depression (TRD)
  • Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

What is SPRAVATO® (esketamine) CIII nasal spray?

SPRAVATO® is a prescription medicine, used along with an antidepressant taken by mouth to treat:

  • Adults with treatment-resistant depression (TRD)
  • Depressive symptoms in adults with major depressive disorder (MDD) with suicidal thoughts or actions

SPRAVATO® is not for use as a medicine to prevent or relieve pain (anesthetic). It is not known if SPRAVATO® is safe or effective as an anesthetic medicine.

It is not known if SPRAVATO® is safe and effective for use in preventing suicide or in reducing suicidal thoughts or actions. SPRAVATO® is not for use in place of hospitalization if your healthcare provider determines that hospitalization is needed, even if improvement is experienced after the first dose of SPRAVATO®.

It is not known if SPRAVATO® is safe and effective in children.

IMPORTANT SAFETY INFORMATION

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

  • Sedation and dissociation. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).
    • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
    • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.

  • Abuse and misuse. There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO®.
    • Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
    • Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.

  • SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.

  • Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed.

SPRAVATO® is not for use in children.

  • Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.

  • How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
    • Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
    • Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings.
    • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.

  • Tell your healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
  • suicide attempts
  • worsening depression
  • thoughts about suicide or dying
  • other unusual changes in behavior or mood

Do not take SPRAVATO® if you:

  • have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
  • have an abnormal connection between your veins and arteries (arteriovenous malformation)
  • have a history of bleeding in the brain
  • are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart or brain problems, including:
    • high blood pressure (hypertension)
    • slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
    • history of heart attack
    • history of stroke
    • heart valve disease or heart failure
    • history of brain injury or any condition where there is increased pressure in the brain
  • have liver problems
  • have ever had a condition called “psychosis” (see, feel, or hear things that are not there, or believe in things that are not true).
  • are pregnant or plan to become pregnant. SPRAVATO® may harm your baby. You should not take SPRAVATO® if you are pregnant.
    • Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
    • If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.
    • There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research- programs/pregnancyregistry/antidepressants/.
  • are breastfeeding or plan to breastfeed. You should not breastfeed during treatment with SPRAVATO®.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

  • You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.
  • Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
  • Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
  • During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
  • You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
  • If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
  • Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
  • If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

What should I avoid while taking SPRAVATO®?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See “What is the most important information I should know about SPRAVATO®?”

What are the possible side effects of SPRAVATO®?

SPRAVATO® may cause serious side effects including:

  • See “What is the most important information I should know about SPRAVATO®?”
  • Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.
  • Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.
  • Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO® when used along with an antidepressant taken by mouth include:

  • feeling disconnected from yourself, your thoughts, feelings and things

around you

  • dizziness
  • nausea
  • feeling sleepy
  • spinning sensation
  • decreased feeling of sensitivity (numbness)
  • feeling anxious
  • lack of energy
  • increased blood pressure
  • vomiting
  • feeling drunk
  • feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.

cp-170363v1

Ben is a volunteer with the SHARE Network, a Janssen Pharmaceuticals, Inc., program made up of people who are dedicated to inspiring others through their personal health journeys and stories of caring. He is a real patient with treatment-resistant depression and was compensated by Janssen Pharmaceuticals, Inc., for his time to develop this content.

If a Janssen treatment has made a difference in your life or the life of a loved one, we hope you will consider joining the?SHARE Network.

Every story is unique. If you are an adult living with TRD, talk to your doctor to figure out a treatment plan that’s right for you.

This information is intended for the use of patients and caregivers in the United States and its territories only. Laws, regulatory requirements and medical practices in pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and its territories.

References:

  1. Rush AJ et al. Am J Psychiatry. 2006;163(11):1905-1917.
  2. Agency for Healthcare Research and Quality. Treatment-Resistant Depression: A Narrative and Systematic Review of Definitions and Methods in Clinical Research Studies. Accessed August 18, 2023. https://www.ahrq.gov/sites/default/files/wysiwyg/research/findings/ta/topicrefinement/trdepression-protocol-amendment.pdf.

© Janssen Pharmaceuticals, Inc. 2023 08/23 cp-406942v1

What is the most important information I should know about SPRAVATO®?

SPRAVATO® can cause serious side effects, including:

  • Sedation and dissociation. SPRAVATO® may cause sleepiness (sedation), fainting, dizziness, spinning sensation, anxiety, or feeling disconnected from yourself, your thoughts, feelings, space and time (dissociation).
    • Tell your healthcare provider right away if you feel like you cannot stay awake or if you feel like you are going to pass out.
    • Your healthcare provider must monitor you for serious side effects for at least 2 hours after taking SPRAVATO®. Your healthcare provider will decide when you are ready to leave the healthcare setting.
  • Abuse and misuse. There is a risk for abuse and physical and psychological dependence with SPRAVATO® treatment. Your healthcare provider should check you for signs of abuse and dependence before and during treatment with SPRAVATO®.
    • Tell your healthcare provider if you have ever abused or been dependent on alcohol, prescription medicines, or street drugs.
    • Your healthcare provider can tell you more about the differences between physical and psychological dependence and drug addiction.
  • SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS). Because of the risks for sedation, dissociation, and abuse and misuse, SPRAVATO® is only available through a restricted program called the SPRAVATO® Risk Evaluation and Mitigation Strategy (REMS) Program. SPRAVATO® can only be administered at healthcare settings certified in the SPRAVATO® REMS Program. Patients treated in outpatient healthcare settings (e.g., medical offices and clinics) must be enrolled in the program.
  • Increased risk of suicidal thoughts and actions. Antidepressant medicines may increase suicidal thoughts and actions in some people 24 years of age and younger, especially within the first few months of treatment or when the dose is changed. SPRAVATO® is not for use in children.
    • Depression and other serious mental illnesses are the most important causes of suicidal thoughts and actions. Some people may have a higher risk of having suicidal thoughts or actions. These include people who have (or have a family history of) depression or a history of suicidal thoughts or actions.
  • How can I watch for and try to prevent suicidal thoughts and actions in myself or a family member?
    • Pay close attention to any changes, especially sudden changes, in mood, behavior, thoughts, or feelings, or if you develop suicidal thoughts or actions.
    • Tell your healthcare provider right away if you have any new or sudden changes in mood, behavior, thoughts, or feelings.
    • Keep all follow-up visits with your healthcare provider as scheduled. Call your healthcare provider between visits as needed, especially if you have concerns about symptoms.
  • Tell your healthcare provider right away if you or your family member have any of the following symptoms, especially if they are new, worse, or worry you:
  • suicide attempts
  • thoughts about suicide or dying
  • worsening depression
  • other unusual changes in behavior or mood

Do not take SPRAVATO® if you:

  • have blood vessel (aneurysmal vascular) disease (including in the brain, chest, abdominal aorta, arms and legs)
  • have an abnormal connection between your veins and arteries (arteriovenous malformation)
  • have a history of bleeding in the brain
  • are allergic to esketamine, ketamine, or any of the other ingredients in SPRAVATO®.

If you are not sure if you have any of the above conditions, talk to your healthcare provider before taking SPRAVATO®.

Before you take SPRAVATO®, tell your healthcare provider about all of your medical conditions, including if you:

  • have heart or brain problems, including:
    • high blood pressure (hypertension)
    • slow or fast heartbeats that cause shortness of breath, chest pain, lightheadedness, or fainting
    • history of heart attack
    • history of stroke
    • heart valve disease or heart failure
    • history of brain injury or any condition where there is increased pressure in the brain
  • have liver problems
  • have ever had a condition called “psychosis” (see, feel, or hear things that are not there, or believe in things that are not true).
  • are pregnant or plan to become pregnant. SPRAVATO® may harm your baby. You should not take SPRAVATO® if you are pregnant.
    • Tell your healthcare provider right away if you become pregnant during treatment with SPRAVATO®.
    • If you are able to become pregnant, talk to your healthcare provider about methods to prevent pregnancy during treatment with SPRAVATO®.
    • There is a pregnancy registry for women who are exposed to SPRAVATO® during pregnancy. The purpose of the registry is to collect information about the health of women exposed to SPRAVATO® and their baby. If you become pregnant during treatment with SPRAVATO®, talk to your healthcare provider about registering with the National Pregnancy Registry for Antidepressants at 1-844-405-6185 or online at https://womensmentalhealth.org/clinical-and-research- programs/pregnancyregistry/antidepressants/.
  • are breastfeeding or plan to breastfeed. You should not breastfeed during treatment with SPRAVATO®.

Tell your healthcare provider about all the medicines that you take, including prescription and over-the-counter medicines, vitamins and herbal supplements. Taking SPRAVATO® with certain medicine may cause side effects.

Especially tell your healthcare provider if you take central nervous system (CNS) depressants, psychostimulants, or monoamine oxidase inhibitors (MAOIs) medicines. Keep a list of them to show to your healthcare provider and pharmacist when you get a new medicine.

How will I take SPRAVATO®?

  • You will take SPRAVATO® nasal spray yourself, under the supervision of a healthcare provider in a healthcare setting. Your healthcare provider will show you how to use the SPRAVATO® nasal spray device.
  • Your healthcare provider will tell you how much SPRAVATO® you will take and when you will take it.
  • Follow your SPRAVATO® treatment schedule exactly as your healthcare provider tells you to.
  • During and after each use of the SPRAVATO® nasal spray device, you will be checked by a healthcare provider who will decide when you are ready to leave the healthcare setting.
  • You will need to plan for a caregiver or family member to drive you home after taking SPRAVATO®.
  • If you miss a SPRAVATO® treatment, your healthcare provider may change your dose and treatment schedule.
  • Some people taking SPRAVATO® get nausea and vomiting. You should not eat for at least 2 hours before taking SPRAVATO® and not drink liquids at least 30 minutes before taking SPRAVATO®.
  • If you take a nasal corticosteroid or nasal decongestant medicine take these medicines at least 1 hour before taking SPRAVATO®.

What should I avoid while taking SPRAVATO®?

Do not drive, operate machinery, or do anything where you need to be completely alert after taking SPRAVATO®. Do not take part in these activities until the next day following a restful sleep. See “What is the most important information I should know about SPRAVATO®?”

What are the possible side effects of SPRAVATO®?

SPRAVATO® may cause serious side effects including:

  • See “What is the most important information I should know about SPRAVATO®?”
  • Increased blood pressure. SPRAVATO® can cause a temporary increase in your blood pressure that may last for about 4 hours after taking a dose. Your healthcare provider will check your blood pressure before taking SPRAVATO® and for at least 2 hours after you take SPRAVATO®. Tell your healthcare provider right away if you get chest pain, shortness of breath, sudden severe headache, change in vision, or seizures after taking SPRAVATO®.
  • Problems with thinking clearly. Tell your healthcare provider if you have problems thinking or remembering.
  • Bladder problems. Tell your healthcare provider if you develop trouble urinating, such as a frequent or urgent need to urinate, pain when urinating, or urinating frequently at night.

The most common side effects of SPRAVATO® when used along with an antidepressant taken by mouth include:

  • feeling disconnected from yourself, your thoughts, feelings and things around you
  • dizziness
  • nausea
  • feeling sleepy
  • spinning sensation
  • decreased feeling of sensitivity (numbness)
  • feeling anxious
  • lack of energy
  • increased blood pressure
  • vomiting
  • feeling drunk
  • feeling very happy or excited

If these common side effects occur, they usually happen right after taking SPRAVATO® and go away the same day.

These are not all the possible side effects of SPRAVATO®.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

Please see full Prescribing Information, including Boxed WARNINGS, and Medication Guide for SPRAVATO® and discuss any questions you may have with your healthcare provider.
cp-170363v1

Ben is a volunteer with the SHARE Network, a Janssen Pharmaceuticals, Inc., program made up of people who are dedicated to inspiring others through their personal health journeys and stories of caring. He is a real patient with treatment-resistant depression and was compensated by Janssen Pharmaceuticals, Inc., for his time to develop this content.

If a Janssen treatment has made a difference in your life or the life of a loved one, we hope you will consider joining the SHARE Network.

Every story is unique. If you are an adult living with TRD, talk to your doctor to figure out a treatment plan that’s right for you.

This information is intended for the use of patients and caregivers in the United States and its territories only. Laws, regulatory requirements and medical practices in pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and its territories.

cp-406942v1

3 Must-Know Child Safety Tips for Peace of Mind at Home or On the Go

2023-09-28T05:01:00

(BPT) – As a parent, you want your child to be happy, healthy and safe. As little ones begin to explore the world around them, parents face more challenges and safety becomes top of mind. Fortunately, a few simple steps can significantly reduce the chance of injury and accidents whether you’re home or away.

The safety experts at the Juvenile Products Manufacturing Association (JPMA), a proud partner of Safety 1st, share three important safety steps all caregivers should take:

Step 1: Move risky items up and add lock systems

Inquisitive kids love to open drawers and cabinets to discover what’s inside. While some spaces may be safe, others may contain things like medicine, cleaning products or breakables like glass. An insider tip: Get on the floor and view the world as your child does — you may be surprised at what you notice from this perspective.

The first step to a safer home is to move items that pose a risk to a high place out of reach of infants and children. Then, install lock systems for any drawers or cabinets that may be within reach.

One of the easiest locking systems to install and use are adhesive magnetic locking systems from Safety 1st. Just peel and stick these low-profile locks on the inside of spaces — the perfect choice for renters or anyone who doesn’t want to damage their cabinets.

Step 2: Install gates and be mindful of stairs

Once children begin to crawl and walk, they take more risks as they explore. This is an important part of their development, but they don’t yet fully understand the dangers. That’s why all caregivers should install gates at the top and bottom of stairs.

Adding a safety gate to a home or apartment doesn’t have to be a complicated process. The Ready to Install Gate from Safety 1st, for example, is a hardware-mounted security gate with a no-trip design. The no-threshold design means no trip hazard at the top of the stairs and one-hand operation with a swing-open door makes it easier for bigger kids and adults to pass through.

On average, every 6 minutes a child in the U.S. goes to the emergency room due to an injury related to falling on the stairs, according to a study by the Nationwide Children’s Hospital. Safety gates can dramatically lower the risk of a child falling on the stairs. Caregivers should also be careful when using stairs if they are holding children. In these cases, go slow, use the handrail with your free hand and move one step at a time.

Step 3: Use safety gear on the go

Child safety isn’t just a priority when at home — it’s important to keep kids secure when out and about as well. Life gets busy and adventures abound, so if you need to get around with ease even when you have your child in tow, make sure you invest in high-quality gear to keep little ones safe.

Vehicle safety is a must, so always use a car seat appropriate for your child’s height and weight. One of the most important car seat safety tips is to make sure to install the car seat correctly. If you’re unsure, some health care offices, public safety departments and local fire departments offer complimentary child safety seat checks.

Depending on your child’s age and your preferences, you may also need a baby carriage or a stroller to keep you moving with safety and ease. Consider a travel system like the Deluxe Grow and Go Flex 8-in-1 that combines these components so you have options to help keep kids secure no matter where you go, with options that can change as they age.

As for stroller safety, make sure to correctly secure and adjust straps and harnesses every time you use them, even if it’s for a short distance. Always apply brakes when stationary to prevent roll-aways. Finally, remember to practice pinch prevention by ensuring baby’s hands are clear when folding and unfolding strollers.

A proactive approach to safety can keep families safe, even when little ones are on the move. Let these three steps guide you at home or while away.

Get to know your cataracts this Healthy Aging Month

2023-09-27T06:01:00

(BPT) – Alcon, the global leader in eye care dedicated to helping people see brilliantly, is highlighting the results of its Alcon Eye On Cataract Survey in light of Healthy Aging Month (September). The global survey, conducted between March and April 2023 in Australia, Brazil, China, Germany, India, Italy, Japan, Spain, South Korea and the United States, set out to evaluate vision and cataract insights among the world’s rapidly aging population.1

The results are clear: healthy vision is a priority for active agers across the globe, and cataract surgery can help turn back the clock for patients’ vision.1 Read more at the infographic below to learn more about the survey results, cataracts and the benefits of presbyopia-correcting intraocular lenses (PC-IOLs) for cataract correction.

References:

  1. Alcon Data on File, 2023

Cooperman Barnabas Medical Center Places Final Steel Beam for New Cancer Center Building

2023-09-26T12:01:00

(BPT) – Cooperman Barnabas Medical Center (CBMC) — part of RWJBarnabas Health, the largest and most comprehensive academic healthcare system in New Jersey — recently raised the final steel beam on its $225 million, freestanding Cancer Center, scheduled for 2025 completion.

Cancer survivors, oncology department staff, board members, and donors added their signatures to the steel beam of the five-story, 137,000-square-foot facility located in Livingston, New Jersey.

The outpatient facility will serve as the northern hub for the integrated oncology services offered by RWJBarnabas Health and Rutgers Cancer Institute of New Jersey, the state’s only National Cancer Institute-designated Comprehensive Cancer Center.

“Cooperman Barnabas Medical Center is a regional leader in cancer care, and with the construction of this state-of-the-art facility, we are setting a new standard for top-quality care,” said Richard L. Davis, the hospital’s President and CEO. “With world-class amenities and a team that includes some of the top cancer specialists in the nation, the new Cancer Center will be a premier destination for patient-centered and research-driven cancer care in this region and beyond.”

“There is absolutely nothing more important to our community than having best-in-class health care. The creation of a state-of-the-art cancer center here at CBMC represents one of the most significant events in this community and continues the ongoing growth and transformation of the Medical Center,” said Bruce Schonbraun, Chair of the Board of Trustees at CBMC.

“Our vision of reimagining cancer care could not have occurred without the generosity and support of our many donors. We are grateful for their support and to everyone who has played a role in bringing this project to life,” Schonbraun added.

Patients will have access to medical, surgical, and radiation oncology services at the new Cancer Center, with amenities that include a wig and prosthetic studio, yoga classes, music therapy, and psychosocial support services. Private infusion rooms and short-term and extended-stay facilities will also be available.

“The Cancer Center at Cooperman Barnabas Medical Center is part of an overall major investment by RWJBarnabas Health and Rutgers Cancer Institute to transform oncology services across the state including the construction of the Jack and Sheryl Morris Cancer Center, the state’s first freestanding cancer hospital,” said Steven K. Libutti, M.D., Director of Rutgers Cancer Institute of New Jersey and Senior Vice President, Oncology Services at RWJBarnabas Health.

The medical center’s partnership with Rutgers Cancer Institute of New Jersey provides patients access to the most advanced treatment options, including clinical trials, CAR T-cell therapy, immunotherapy, and precision medicine.

“This new Cancer Center will be synonymous with clinical excellence, collaboration, and a commitment to integrated care, delivered by world-class physicians and specialists,” said Michael Scoppetuolo, M.D., Medical Director of the Cancer Center at CBMC. “This is what the future of cancer care looks like in the Garden State and beyond. I’m honored to be a part of it.”

“Cancer treatment is getting more targeted and precise every year,” added Alison Grann, M.D., Chair of the hospital’s Department of Radiation Oncology and the Northern Region Director of Radiation Oncology, RWJBarnabas Health. “The Cancer Center will provide patients with the most advanced multidisciplinary, patient-centric cancer care available in one central location.”

More information about the new center is available online, at rwjbh.org/cbmccancercenter.